Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study Conference

Schmidt, M, Schmoll, H, Mayer, F et al. (2011). Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study . JOURNAL OF CLINICAL ONCOLOGY, 29(15), 10.1200/jco.2011.29.15_suppl.e14114

Industry Collaboration International Collaboration

cited authors

  • Schmidt, M; Schmoll, H; Mayer, F; Riera, J; Hapke, G; Andel, J; Nitsche, D; Ziebermayr, R; Weith, E; Schroff, M; Tschaika, M; Wittig, B

authors

publication date

  • May 20, 2011

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 29

issue

  • 15